An NCI-designated Comprehensive Cancer Center

Sariah Liu, M.D., Ph.D.

Medical Oncologist
Research Focus
  • Drug metabolism and impact from genetic mutations
Appointments
Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Other Languages Spoken
  • Mandarin Chinese
A talented researcher and clinician, Dr. Sariah Liu, believes cancer treatment should be personalized based on each patient’s unique situation including genetic profile. That is why she pursued a doctorate in pharmacology in addition to her medical degree.
 
Raised in China, Dr. Liu attended medical school at Shanghai Medical University. Later she earned her Ph.D. at USC, focusing on drug metabolism and how it's impacted by genetic mutations. She went on to complete her internship and residency at USC, followed by fellowship in hematology and oncology at University of California San Diego.
 
Based in our South Bay facility, Dr. Liu has authored numerous scientific papers while making patient care her priority. “I am dedicated to providing patients with high-quality care,” she says, “to helping them understand their diseases and navigate through treatment decisions, and to supporting them during the uphill battle fighting against cancer.”
 

Locations

City of Hope South Bay, 5215 Torrance Blvd

Torrance, CA 90503

  • Nikanjam M, Liu S, Yang J, Kurzrock R. Dosing three drug combinations that include targeted anti-cancer agents: Analysis of 37,763 patients. The Oncologist 22 (2017): 576-584.
  • Liu S, Nikanjam M*, Kurzrock R. Dosing de novo combinations of two targeted drugs: towards a customized precision medicine approach to advanced cancers. Oncotarget. 7(2016):11310-11320.
  • Nikanjam M, Liu S, Kurzrock R. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer. 139 (2016): 2135–2141.
  • Liu S, Kurzrock R, Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers; Oncotarget, Jan 2016 Epub ahead of print 7023
  • Liu S, Kurzrock R, Understanding toxicities of targeted agents: Implications for antitumor activity and management; Seminars in Oncology, Dec 2015; 42(6): 863-875.
  • Liu S, Kurzrock R, Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms, Cancer Treatment Review, Aug 2014; 40(7):883-91.
  • Liu SV, Liu S, Pinski J, Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer, Expert Opinion on Investigational Drugs, Jun 2011; 20(6): 769-78.
  • Baydur A, Alavy B, Nawathe A, Liu S, et al. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis, Clinical Respiratory Journal, Jul 2011; 5(3): 156-64.
  • Liu S, Beringer P, Hidayat L, et al. Probenecid, but not cystic fibrosis alters the clearance of fexofenadine, Journal of Clinical Pharmacology, Aug 2008; 48: 957-965.
  • Goicoechea M, Liu S, Best B, et al. Greater Tenofovir-associated renal function decline with protease inhibitor–based versus nonnucleoside reverse-transcriptase inhibitor–based therapy, The Journal of Infectious Diseases 2008;197:102-108
  • Beringer P, Kriengkauykiat J, Zhang X, Hidayat L, Liu S, et al. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis. Pharmacotherapy 2008 Jul; 28(7): 883-894.
  • Liu S, Frye R, Branch R, et al. Effect of age and postoperative time on cytochrome P450 enzyme activity following liver transplantation, Journal of Clinical Pharmacology 2005;45:666-673
  • Chin A, Liu S, Ting-Chan J, et al. Extended stability of ascorbic acid in 5% dextrose injection and 0.9% sodium chloride injection. American Journal of Health-System Pharmacy 2005 62(10):1073-1074.

Abstracts/Posters

  • Nikanjam M, Liu S, Kurzrock R. Dosing de novo two-drug combinations based on 20,202 patients in Phase I-III clinical trials; ASCO annual meeting, Chicago, Jun 2016
  • Liu S, Ann Mohrbacher, Dan Douer, et al. Combination therapy with BCNU/Etoposide/Melphalan (BEM) as conditioning regimen for autologous stem cell transplant in multiple myeloma, Blood (ASH Annual Meeting Abstracts), Nov 2010; 116: 4587.
  • Liu S, O’Connell C, et al. Triple anticoagulation therapy in a patient with atrial fibrillation, ACP regional meeting, Los Angeles, 2010.
  • Liu S, Frye R, Branch R et al. Effect of age and postoperative time on cytochrome P450 enzyme activity following liver transplantation, American Society of Clinical Pharmacology annual conference, Orlando, Florida, 2005.
In The News